FDA grants orphan drug status to experimental oral treatment for inherited vision loss
Editorial illustration — Press Pass USAThe U.S. Food and Drug Administration has granted orphan drug designation to an experimental oral treatment for a rare inherited form of vision loss, its developer Octant announced Wednesday.
The designation covers OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa, a genetic condition in which the light-sensing cells of the retina gradually deteriorate. OCT-980 is an investigational small molecule designed to correct misfolded rhodopsin protein and restore its normal trafficking inside photoreceptor cells, according to the company.
Orphan drug designation is not an approval: it supports development of treatments for rare diseases through incentives including potential tax credits for qualified clinical trials, exemption from certain FDA application fees, and eligibility for seven years of U.S. market exclusivity if the drug is eventually approved. A Phase 1b/2 study of OCT-980 is underway at U.S. sites, registered as NCT07408232; the healthy-volunteer Phase 1a portion is complete, and the patient portion is enrolling adults with the condition, with primary completion estimated for November 2028.
No safety or efficacy results in patients have been reported yet, and the treatment remains investigational — it is not available as a prescribed therapy while the trial continues.
Sources: Octant, Inc. news release (Oct 28, 2026); Ophthalmology Times (Oct 28, 2026).
Sponsored